Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 4—April 2008
Synopsis

Potential Use of Antiviral Agents in Polio Eradication

Armando M. De Palma*, Gerhard Pürstinger†, Eva Wimmer†, Amy K. Patick‡, Koen Andries§, Bart Rombaut¶, Erik De Clercq*, and Johan Neyts*Comments to Author 
Author affiliations: *University of Leuven, Leuven, Belgium; †University of Innsbruck, Innsbruck, Austria; ‡Pfizer Global Research and Development, San Diego, California, USA; §J&J Pharmaceutical Research and Development, Beerse, Belgium; ¶Vrije Universiteit Brussel, Brussels, Belgium;

Main Article

Table

Inhibitory activity of selected compounds against replication of poliovirus Sabin strains 1, 2, and 3 in HeLa cells, as determined by a CPE reduction assay*

Compound EC50 (µmol/L)
Toxicity (CC50;µmol/L) TI (min–max)
PV1 PV2 PV3
Capsid binders
Pirodavir analog (R78206) 0.76 ± 0.18 0.22 ± 0.19 0.11 ± 0.10 27 ± 34 35–245
Pleconaril >100 1.1 ± 0.6 0.22 ± 0.15 66 ± 6 <0.66–300
Pirodavir (R77975)
10 ± 1
1.7 ± 0.1
0.56 ± 0.03
>100
>10–>179
Protease inhibitors
Rupintrivir 0.022 ± 0.028 0.041 ± 0.024 0.0052 ± 0.0046 >100 >2,439–>19,231
Compound 1
0.26 ± 0.24
0.31 ± 0 .21
0.060 ± 0 .000
>100
>322–>1,667
3A inhibitor
Enviroxime
0.2 ± 0.25
0.056 ± 0.020
0.035 ± 0.029
58 ± 6
290–1,657
Nucleoside analogs
Ribavirin 57 ± 13 64 ± 4 55 ± 7 >100 >1.6–>1.8
2'-C-methylcytidine† 15 ± 18 29 ± 27 3.9 ± 2.3 >100 >3.4–>26
2'-C-methyladenosine 5.5 ± 0.0 5.6 ± 0.1 5.4 ± 0.4 84 ± 0 15
4’-azidocytidine
>100
>100
>100
>100
><1
2C inhibitors
HBB 300 ± 68 225 ± 128 295 ± 88 >400 >1.3–>1.8
MRL-1237
5.3 ± 0.3
4.6 ± 1.4
3.8 ± 2.5
>100
>19–>26
Unknown target
MDL-860 6.0 ± 1.6 3.6 ± 2.2 2.2 ± 1.5 >100 >17–>45

*CPE, cytopathic effect; EC50, 50% effective concentration; CC50, 50% cytotoxic concentration; PV, poliovirus; TI, therapeutic index (CC50/EC50); min, minimum; max, maximum; HBB, 2-(α-hydroxybenzyl)-benzimidazole.
†Valopicitabine (oral valine ester prodrug of 2′-C-methylcytidine).

Main Article

Page created: July 16, 2010
Page updated: July 16, 2010
Page reviewed: July 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external